FDA reviews NDA for VIVUS' Qnexa

Tuesday, December 27, 2011 11:11 AM

VIVUS has reported that the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA is scheduled to review the Company's New Drug Application (NDA) for Qnexa for the treatment of obesity on February 22, 2012. VIVUS resubmitted the NDA on seeking approval to market Qnexa in the United States. The FDA has accepted the NDA for review. The target date for the FDA to complete its review of the Qnexa NDA is April 17, 2012.

Qnexa is an investigational drug candidate being developed to address weight loss, type 2 diabetes and obstructive sleep apnea. Qnexa is a once-a-day, proprietary, oral, controlled-release formulation of low-dose phentermine and topiramate, which is designed to decrease appetite and increase satiety (the sense of feeling full), the two main mechanisms that impact eating behavior. In phase II and III clinical data to date, patients taking Qnexa have demonstrated statistically significant weight loss, glycemic control, and improvement in cardiovascular risk factors, when used in combination with a diet and lifestyle modification program.

CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

Date»
- 2013
- 2012
- 2011
- 2010
- 2009
- 2008
- 2007
Region»
- U.S.
- Europe
- Asia
- Emerging Markets
- Global
Company Index
Search

May 20

IRB consolidation trend continues, as private equity firm Audax buys majority stake in Chesapeake

Quintiles, Merck Serono ink exclusive partnership

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

May

INC Research, PPD, inVentiv named top CROs
Yet most CROs slipping in ability to manage site relationships

R&D cuts by sponsors spur more collaboration, innovation
New strategies share pipeline activity costs

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

April

20 innovators changing the face of the clinical trials industry
The CenterWatch Monthly honors individuals, teams and companies for their forward-thinking ideas and their ability to implement them.

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

centerwatch.com/jobwatch

Featured Jobs

More Jobs

About CenterWatch News Online: Developed by CenterWatch, the trusted experts and recognized leaders in clinical research news and analysis, CenterWatch News Online (formerly Clinical Trials Today) is a one-stop, comprehensive resource for clinical research professionals spanning all sectors of the clinical trials industry.

Order Custom PDF Reprints: CenterWatch offers custom PDF reprints of any new or archived article appearing on CenterWatch News Online. This document can be posted on your company's Intranet or web site or used in corporate marketing promotions.To purchase a custom PDF reprint, contact Sales at sales@centerwatch.com or (617) 948-5100.

Contact Us: Editorial | Advertise | View Media Guide

More Resources From CenterWatch

Publications: Newsletters | White Papers | Industry Analysis & Special Reports
Training & Education: Clinical Research Guides | SOPs | Patient Education Resources
Online Services: Research Center and Industry Provider Profiles | Clinical Trials Data Library | Content Licensing | Drugs in Clinial Trials | JobWatch | Clinical Trials | TrialWatch for Sites and Sponsors/CROs